---
title: "Krystal Biotech | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 119.22 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294683225.md"
datetime: "2026-08-03T11:06:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294683225.md)
  - [en](https://longbridge.com/en/news/294683225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294683225.md)
generator: "portal-rs"
---

# Krystal Biotech | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 119.22 M

Revenue: As of FY2026 Q2, the actual value is USD 119.22 M, missing the estimate of USD 121.04 M.

EPS: As of FY2026 Q2, the actual value is USD 1.79, beating the estimate of USD 1.6275.

EBIT: As of FY2026 Q2, the actual value is USD 66.08 M.

The provided reference, a Form 8-K filing by Krystal Biotech, Inc., announces the release of its financial results for the quarter ending June 30, 2026, on August 3, 2026 . However, the actual financial results, operational metrics, or outlook/guidance are not included within this document . These details are referenced as being in an attached Exhibit 99.1, which is not provided in the reference text . Therefore, no financial or operational metrics, nor any outlook or guidance, can be extracted from the given text .

### Related Stocks

- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)

## Related News & Research

- [Krystal Biotech CEO Krish S. Krishnan sells USD 7.59 million in common shares](https://longbridge.com/en/news/298080936.md)
- [Krystal Biotech (KRYS) After Its Q2 Beat Is The Valuation Case Still Intact](https://longbridge.com/en/news/295003762.md)
- [Analyst Backs Krystal with Buy Rating on Vyjuvek Launch Momentum and Rare-Disease Pipeline Upside](https://longbridge.com/en/news/294716681.md)
- [Krystal Biotech files patent response citing single-patient KB801 corneal closure](https://longbridge.com/en/news/293389611.md)
- [Krystal Biotech EVP, General Counsel John C. Thomas disposes of USD 347,270 in common shares](https://longbridge.com/en/news/291014069.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**